Explore the latest trial data from the Hematology Annual Meeting in San Diego. This activity includes critical analysis of the clinical trial data and discussion on how these data may impact clinical practice.
1.25 AMA PRA Category 1 Credits™
1.25 Contact Hours
Dec 7, 2018
Dec 7, 2019
- Sagar Lonial, MD, Winship Cancer Institute, Emory University, Atlanta, Georgia, United States
- Nina Shah, MD, University of California San Francisco, San Francisco, California, United States
Abstract #LBA-2: Phase 3 Randomized Study of Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Ineligible for Transplant (MAIA)
Abstract #598: Results of the Pivotal STORM Study (Part 2) in Penta-Refractory Multiple Myeloma (MM): Deep and Durable Responses with Oral Selinexor Plus Low Dose Dexamethasone in Patients with Penta Exposed and Triple Class-Refractory MM
Abstract #303: Phase 2 Study of Venetoclax Plus Carfilzomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma
Abstract #488: Initial Results from a Phase 1 Clinical Study of bb21217, a Next-Generation Anti Bcma CAR T Therapy
Abstract #957: JCARH125, Anti-BCMA CAR T-cell Therapy for Relapsed/Refractory Multiple Myeloma: Initial Proof of Concept Results from a Phase 1/2 Multicenter Study (EVOLVE)
Chronic Lymphocytic Leukemia
- Jacqueline Barrientos, MD, MS, Zucker School of Medicine at Hofstra/Northwell, Lake Success, New York, United States
- Anthony Mato, MD, Memorial Sloan Kettering Cancer Center, New York, New York, United States
Abstract #LBA-4: Randomized Phase III Study of Ibrutinib (PCI-32765)-Based Therapy Vs. Standard Fludarabine, Cyclophosphamide, and Rituximab (FCR) Chemoimmunotherapy in Untreated Younger Patients with Chronic Lymphocytic Leukemia (CLL): A Trial of the ECOG-ACRIN Cancer Research Group (E1912)
Abstract #692: Acalabrutinib in Treatment-Naive (TN) Chronic Lymphocytic Leukemia (CLL): Updated Results from the Phase 1/2 ACE-CL-001 Study
Abstract #297: Phase I/II Study of Umbralisib (TGR-1202) in Combination with Ublituximab (TG-1101) and Pembrolizumab in Patients with Relapsed/Refractory CLL and Richter’s Transformation
Abstract #298: Prospective Clinical Trial of Anti-CD19 CAR T Cells in Combination with Ibrutinib for the Treatment of Chronic Lymphocytic Leukemia Shows a High Response Rate
- Alison Moskowitz, MD, Memorial Sloan Cancer Center, New York, New York, United States
- Barbara Pro, MD, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, Illinois, United States
Abstract #997: The ECHELON-2 Trial: Results of a Randomized, Double-Blind, Active-Controlled Phase 3 Study of Brentuximab Vedotin and CHP (A+CHP) Versus CHOP in the Frontline Treatment of Patients with CD30+ Peripheral T-Cell Lymphomas
Abstract #681: Clinical Responses to CAR.CD30-T Cells in Patients with CD30+ Lymphomas Relapsed after Multiple Treatments Including Brentuximab Vedotin
Abstract #927: Response-Adapted Therapy with Nivolumab and Brentuximab Vedotin (BV), Followed By BV and Bendamustine for Suboptimal Response, in Children, Adolescents, and Young Adults with Standard-Risk Relapsed/Refractory Classical Hodgkin Lymphoma
Abstract #682: Tislelizumab (BGB-A317) for Relapsed/Refractory Classical Hodgkin Lymphoma: Preliminary Efficacy and Safety Results from a Phase 2 Study
Acute Myeloid Lymphoma
- Daniel DeAngelo, MD, PhD, Dana-Farber Cancer Institute, Boston, Massachusetts, United States
- Andrew Wei, MD, PhD, Alfred Hospital and Monash University, Melbourne, Australia
Abstract #284: Venetoclax with Low-Dose Cytarabine Induces Rapid, Deep, and Durable Responses in Previously Untreated Older Adults with AML Ineligible for Intensive Chemotherapy
Abstract #560: Ivosidenib or Enasidenib Combined with Induction and Consolidation Chemotherapy in Patients with Newly Diagnosed AML with an IDH1 or IDH2 Mutation Is Safe, Effective, and Leads to MRD-Negative Complete Remissions
Abstract #287: Enasidenib Is Highly Active in Previously Untreated IDH2 Mutant AML: Early Results from the Beat AML Master Trial
Abstract #331: Uproleselan (GMI-1271), an E-Selectin Antagonist, Improves the Efficacy and Safety of Chemotherapy in Relapsed/Refractory (R/R) and Newly Diagnosed Older Patients with Acute Myeloid Leukemia: Final, Correlative and Subgroup Analyses
Abstract #286: Interim Analysis of Phase II Study of Venetoclax with 10-Day Decitabine (DEC10-VEN) in Acute Myeloid Leukemia and Myelodysplastic Syndrome
Abstract #563: Efficacy and Safety of Single-Agent Quizartinib (Q), a Potent and Selective FLT3 Inhibitor (FLT3i), in Patients (pts) with FLT3-Internal Tandem Duplication (FLT3-ITD)–Mutated Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) Enrolled in the Global, Phase 3, Randomized Controlled Quantum-R Trial
Acute Lymphoblastic Leukemia
- Jae H. Park, MD, Memorial Sloan Kettering Cancer Center, New York, New York, United States
Abstract #33: Results of SWOG 1318: A Phase 2 Trial of Blinatumomab Followed By Pomp (Prednisone, Vincristine, Methotrexate, 6-Mercaptopurine) Maintenance in Elderly Patients with Newly Diagnosed Philadelphia Chromosome Negative B-Cell Acute Lymphoblastic Leukemia
Abstract #31: Nilotinib (Tasigna®) and Low Intensity Chemotherapy for First-Line Treatment of Elderly Patients with BCR-ABL1- Positive Acute Lymphoblastic Leukemia: Final Results of a Prospective Multicenter Trial (EWALL-PH02)
Abstract #34: Inotuzumab Ozogamicin in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) Vs. Standard Intensive Chemotherapy (hyper-CVAD) As Frontline Therapy for Older Patients with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia (ALL): A Propensity Score Analysis
Abstract #895: Updated Analysis of the Efficacy and Safety of Tisagenlecleucel in Pediatric and Young Adult Patients with Relapsed/Refractory (r/r) Acute Lymphoblastic Leukemia
Abstract #897: Updated Phase 1 Results of Zuma-3: Kte-C19, an Anti-CD19 Chimeric Antigen Receptor T Cell Therapy, in Adult Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia
Jacqueline Barrientos, MD, MSZucker School of Medicine at Hofstra/Northwell
Lake Success, New York, United States
Daniel DeAngelo, MD, PhDDana-Farber Cancer Institute
Boston, Massachusetts, United States
Sagar Lonial, MDWinship Cancer Institute
Atlanta, Georgia, United States
Anthony Mato, MD Memorial Sloan Kettering Cancer Center
New York, New York, United States
Alison Moskowitz, MDMemorial Sloan Cancer Center
New York, New York, United States
Jae H. Park, MDMemorial Sloan Kettering Cancer Center
New York, New York, United States
Barbara Pro, MDRobert H. Lurie Comprehensive Cancer Center of Northwestern University
Chicago, Illinois, United States
Andrew Wei, MD, PhDAlfred Hospital and Monash University
Nina Shah, MDUniversity of California San Francisco
San Francisco, California, United States
This educational activity is designed to meet the needs of practicing hematologists, oncologists, oncology nurses, researchers, and other health care professionals involved and/or interested in the management of patients with hematologic malignancies and the consequences of these diseases.
After successful completion of this educational activity, participants should be able to:
- Discuss key data from the conference
- Apply key data from the conference to clinical practice, as appropriate
This educational activity is supported by a grant from AbbVie; AstraZeneca; Celgene Corporation; and Seattle Genetics, Inc.
prIME Oncology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
prIME Oncology designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
prIME Oncology is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.
This activity has been approved for 1.25 contact hours.
This activity is provided by prIME Oncology.
prIME Oncology complies with all Sunshine Act reporting requirements as outlined by CMS and applicable manufacturers and with EFPIA Disclosure Code reporting requirements.
Method of Participation
Disclosure of Relevant Financial Relationships
prIME Oncology requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to prIME Oncology policy. prIME Oncology is committed to providing its learners with high-quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.
The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interest related to the content of this activity:
Dr Barrientos has disclosed that she has received consulting fees from AbbVie, Gilead, and Pharmacyclics. She has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her presentation.
Dr DeAngelo has disclosed that he has received consulting fees from Amgen, Novartis Oncology, Pfizer, and Takeda. He also performed contracted research for AbbVie, BluePoint, and GlycoMimetics. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.
Dr Lonial has disclosed that he has received consulting fees from Amgen, Bristol-Myers Squibb, Celgene Corporation, GlaxoSmithKline, Karyopharm Therapeutics, Novartis Oncology, and Takeda. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.
Dr Mato has disclosed that he has received consulting fees from Acinta Pharmaceuticals, AstraZeneca, Janssen, Pharmacyclics, and TG Therapeutics. He has performed contracted research for AbbVie, Acinta Pharmaceuticals, Celgene, and Johnson & Johnson. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.
Dr Moskowitz has disclosed that he received consulting fees from Seattle Genetics. He has also performed contracted for Bristol-Myers Squibb, Incyte, Merck, and Seattle Genetics. He has received honoraria from BDC Therapeutics, Bristol-Myers Squibb, Merck, Seattle Genetics, and Takeda. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her presentation.
Dr Park has disclosed that he has received consulting fees from Amgen, GlaxoSmithKline, Kite Pharma, and Novartis Oncology. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.
Dr Pro has disclosed that she has received consulting fees from Seattle Genetics and Takeda. She has also performed contracted research for Seattle Genetics and Takeda. She has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her presentation.
Dr Shah has disclosed that she has received consulting fees from Amgen; Bristol-Myers Squibb; Kite Pharma; Nektar Therapeutics; Nkarta, Inc.; Oncopeptides; Seattle Genetics, and TeneoBio. She has also performed contracted research for BlueBird, Celgene Corporation, Janssen, and Sutra. She has ownership interest in Indapta Therapeutics. She has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her presentation.
The employees of prIME Oncology have disclosed no relevant financial relationships.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Disclosure Regarding Unlabeled Use
This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.